Banner
Identification
Name Capromab
Accession Number DB00089 (BIOD00080, BTD00080)
Type biotech
Groups approved
Description

Murine IgG1 monoclonal antibody 7E11-C5.3 antibody conjugated to linker chelator peptide group for indium attachment
Protein structure Db00089
Display: 3D Structure
Protein chemical formula Not Available
Protein average weight Not Available
Sequences
Synonyms
  • Capromab pendetide
  • In 111 Capromab pendetide
  • ProstaScint
Brand names
  • ProstaScint (Cytogen Corp.)
Brand name mixtures Not Available
Categories
  • Imaging Agents
CAS number 145464-28-4
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication For diagnosis of prostate cancer and detection of intra-pelvic metastases.
Pharmacodynamics Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.
Mechanism of action Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Absorption Not Available
Volume of distribution
  • 4 ± 2.1 L
Protein binding Not Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
Route of elimination Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
Half life Not Available
Clearance
  • 42 +/- 22 mL/hr
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers Not Available
Packagers
Dosage forms Not Available
Prices
Unit description Cost Unit
Prostascint kit 1584.0 USD kit
Patents Not Available
Properties
State liquid
Melting point 61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Experimental Properties Not Available
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
Drug Product Database 0 Link_out
Wikipedia http://en.wikipedia.org/wiki/Capromab Link_out
ATC Codes
  • V09IB04
AHFS Codes Not Available
PDB Entries
FDA label show (1.6 MB)
MSDS Not Available
Interactions
Drug Interactions
Drug Interaction
Food Interactions Not Available
Targets

1. Glutamate carboxypeptidase 2

Pharmacological action: yes
Actions: other/unknown

Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC

Organism class: human
UniProt ID: Q04609 Link_out
Gene: FOLH1 Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. Pubmed
  2. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. Pubmed
  3. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. Pubmed
  4. Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
Comments
Drug created on June 13, 2005 07:24 / Updated on September 29, 2010 14:34

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.